Markolf Hanefeld

Q: What Schools Are Affiliated With Markolf Hanefeld

Markolf Hanefeld is affiliated with the following schools: University of Oxford, Stanford University, Johns Hopkins University, TU Dresden, Harvard University

Markolf Hanefeld's AcademicInfluence.com Rankings

Markolf Hanefeld

Philosophy

#6119

World Rank

#9093

Historical Rank

Logic

#3308

World Rank

#4444

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Markolf Hanefeld's Degrees

Doctorate Medicine Harvard University

Why Is Markolf Hanefeld Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Markolf Hanefeld's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial (2002) (2389)
Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial (2006) (1681)
Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. (2003) (1655)
Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial (2009) (1317)
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial (2019) (1256)
Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up (1996) (930)
Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis. (2007) (800)
Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. (2004) (629)
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus (2006) (628)
Postchallenge plasma glucose and glycemic spikes are more strongly associated with atherosclerosis than fasting glucose or HbA1c level. (2000) (556)
Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III Study). ALADIN III Study Group. Alpha-Lipoic Acid in Diabetic Neuropathy. (1999) (400)
Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant alpha-lipoic acid. A 3-week multicentre randomized controlled trial (ALADIN Study). (1995) (400)
Postprandial glucose regulation and diabetic complications. (2004) (346)
Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial (2019) (311)
Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial. (2004) (271)
Acarbose Slows Progression of Intima-Media Thickness of the Carotid Arteries in Subjects With Impaired Glucose Tolerance (2004) (257)
One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes. (2004) (246)
In type 2 diabetes, rosiglitazone therapy for insulin resistance ameliorates endothelial dysfunction independent of glucose control. (2004) (240)
The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study. (2008) (238)
Insulin secretion and insulin sensitivity pattern is different in isolated impaired glucose tolerance and impaired fasting glucose: the risk factor in Impaired Glucose Tolerance for Atherosclerosis and Diabetes study. (2003) (235)
Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial (2010) (231)
Postprandial plasma glucose is an independent risk factor for increased carotid intima-media thickness in non-diabetic individuals. (1999) (230)
Therapeutic Potentials of Acarbose as First-Line Drug in NIDDM Insufficiently Treated With Diet Alone (1991) (193)
Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial (2016) (193)
Efficacy and Safety of Exenatide Once Weekly Versus Metformin, Pioglitazone, and Sitagliptin Used as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4) (2012) (190)
Diabetes Intervention Study: Multi-Intervention Trial in Newly Diagnosed NIDDM (1991) (185)
Long‐term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study (2005) (179)
Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes* (2007) (178)
Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes (2005) (169)
Anti-inflammatory effects of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity C-reactive protein: the PIOSTAT Study. (2007) (165)
The STOP-NIDDM Trial: An international study on the efficacy of an α-glucosidase inhibitor to prevent type 2 diabetes in a population with impaired glucose tolerance: rationale, design, and preliminary screening data (1998) (163)
Postprandial glucose regulation: new data and new implications. (2005) (161)
Subclinical inflammation is strongly related to insulin resistance but not to impaired insulin secretion in a high risk population for diabetes. (2002) (157)
Insulin-resistant patients with type 2 diabetes mellitus have higher serum leptin levels independently of body fat mass (2002) (156)
Design and baseline characteristics of participants in the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial on the cardiovascular effects of dulaglutide (2018) (156)
The effects of orlistat on body weight and glycaemic control in overweight patients with type 2 diabetes: a randomized, placebo‐controlled trial (2002) (151)
Postprandial hyperglycaemia and cardiovascular complications of diabetes: an update. (2006) (150)
Increased intimal-medial thickness in newly detected type 2 diabetes: risk factors. (1999) (148)
A long‐term comparison of pioglitazone and gliclazide in patients with Type 2 diabetes mellitus: a randomized, double‐blind, parallel‐group comparison trial (2005) (144)
Relationship Between Hypoglycemic Episodes and Ventricular Arrhythmias in Patients With Type 2 Diabetes and Cardiovascular Diseases: Silent Hypoglycemias and Silent Arrhythmias (2014) (141)
Natural History of Cardiovascular Disease in Patients With Diabetes (2008) (140)
Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD): study design and protocol (2005) (140)
Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant α-lipoic acid (1995) (137)
Differential White Blood Cell Count and Type 2 Diabetes: Systematic Review and Meta-Analysis of Cross-Sectional and Prospective Studies (2010) (136)
Rapid and short-acting mealtime insulin secretion with nateglinide controls both prandial and mean glycemia. (2000) (131)
Metabolic diseases and their possible link to risk indicators of periodontitis. (2000) (130)
Post‐challenge hyperglycaemia relates more strongly than fasting hyperglycaemia with carotid intima‐media thickness: the RIAD Study (2000) (122)
Efficacy and safety of lixisenatide once daily vs. placebo in people with Type 2 diabetes insufficiently controlled on metformin (GetGoal‐F1) (2014) (119)
Prandial Options to Advance Basal Insulin Glargine Therapy: Testing Lixisenatide Plus Basal Insulin Versus Insulin Glulisine Either as Basal-Plus or Basal-Bolus in Type 2 Diabetes: The GetGoal Duo-2 Trial (2016) (117)
The role of acarbose in the treatment of non-insulin-dependent diabetes mellitus. (1998) (116)
Evaluation of a Diabetes Management System Based on Practice Guidelines, Integrated Care, and Continuous Quality Management in a Federal State of Germany (2008) (114)
Das Metabolische Syndrom (2006) (112)
The Finnish Diabetes Risk Score is associated with insulin resistance and progression towards type 2 diabetes. (2009) (111)
Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis (2010) (108)
Acarbose for the prevention of Type 2 diabetes, hypertension and cardiovascular disease in subjects with impaired glucose tolerance: facts and interpretations concerning the critical analysis of the STOP-NIDDM Trial data (2004) (108)
Beneficial effects of once-daily lixisenatide on overall and postprandial glycemic levels without significant excess of hypoglycemia in type 2 diabetes inadequately controlled on a sulfonylurea with or without metformin (GetGoal-S). (2014) (106)
Is Hyperglycemia a Cardiovascular Risk Factor? (2011) (104)
In vivo evidence for increased oxidation of circulating LDL in impaired glucose tolerance. (2002) (103)
Subclinical inflammation in newly detected Type II diabetes and impaired glucose tolerance. (2002) (99)
Hypoglycemia and Cardiovascular Risk: Is There a Major Link? (2016) (91)
In vivo evidence for increased apolipoprotein A-I catabolism in subjects with impaired glucose tolerance. (1998) (88)
Rosiglitazone RECORD study: glucose control outcomes at 18 months (2007) (88)
Impaired fasting glucose is not a risk factor for atherosclerosis (1999) (86)
Cardiovascular benefits and safety profile of acarbose therapy in prediabetes and established type 2 diabetes (2007) (83)
Association of the calpain-10 gene with type 2 diabetes in Europeans: results of pooled and meta-analyses. (2006) (83)
Association of sulphonylurea treatment with all-cause and cardiovascular mortality: A systematic review and meta-analysis of observational studies (2013) (82)
Pharmacokinetics and clinical efficacy of pioglitazone. (2001) (81)
The Postprandial State and the Risk of Atherosclerosis (1997) (80)
The STOP-NIDDM Trial: an international study on the efficacy of an alpha-glucosidase inhibitor to prevent type 2 diabetes in a population with impaired glucose tolerance: rationale, design, and preliminary screening data. Study to Prevent Non-Insulin-Dependent Diabetes Mellitus. (1998) (79)
Prandial insulin substitution with insulin lispro or insulin lispro mid mixture vs. basal therapy with insulin glargine: a randomized controlled trial in patients with type 2 diabetes beginning insulin therapy. (2006) (79)
Relationship between fasting plasma glucose, atherosclerosis risk factors and carotid intima media thickness in non-diabetic individuals (1998) (78)
Control of post-prandial hyperglycemia--an essential part of good diabetes treatment and prevention of cardiovascular complications. (2002) (77)
Very fast ultracentrifugation of serum lipoproteins: influence on lipoprotein separation and composition. (1995) (76)
High-Sensitivity C-Reactive Protein Predicts Cardiovascular Risk in Diabetic and Nondiabetic Patients: Effects of Insulin-Sensitizing Treatment with Pioglitazone (2010) (76)
Impact of glucagon response on postprandial hyperglycemia in men with impaired glucose tolerance and type 2 diabetes mellitus. (2005) (75)
Impact of the individual components of the metabolic syndrome and their different combinations on the prevalence of atherosclerotic vascular disease in type 2 diabetes: the Diabetes in Germany (DIG) study (2007) (73)
Cardiac implications of hypoglycaemia in patients with diabetes – a systematic review (2013) (69)
Effects of p-chlorophenoxyisobutyric acid (CPIB) on the human liver. (1980) (66)
Effect of simvastatin and/or pioglitazone on insulin resistance, insulin secretion, adiponectin, and proinsulin levels in nondiabetic patients at cardiovascular risk--the PIOSTAT Study. (2007) (66)
Ala12Ala genotype of the peroxisome proliferator-activated receptor gamma2 protects against atherosclerosis. (2004) (65)
Acarbose: oral antidiabetes drug with additional cardiovascular benefits (2008) (63)
European study on dose-response relationship of acarbose as a first-line drug in non-insulin-dependent diabetes mellitus: efficacy and safety of low and high doses (1998) (61)
Efficacy and tolerability of saxagliptin compared with glimepiride in elderly patients with type 2 diabetes: a randomized, controlled study (GENERATION) (2015) (61)
Improved metabolic control by Ipomoea batatas (Caiapo) is associated with increased adiponectin and decreased fibrinogen levels in type 2 diabetic subjects (2008) (59)
Structured health care for subjects with diabetic foot ulcers results in a reduction of major amputation rates (2013) (58)
An update on preventive and regenerative therapies in diabetes mellitus. (2009) (58)
The lipid triad in type 2 diabetes - prevalence and relevance of hypertriglyceridaemia/low high-density lipoprotein syndrome in type 2 diabetes. (2004) (57)
Risk of and risk factors for hypoglycemia and associated arrhythmias in patients with type 2 diabetes and cardiovascular disease: a cohort study under real-world conditions (2015) (56)
Comparison of the prevalence of the metabolic syndrome by WHO, AHA/NHLBI, and IDF definitions in a German population with type 2 diabetes: the Diabetes in Germany (DIG) Study. (2007) (55)
Glycemic control and treatment failure with pioglitazone versus glibenclamide in type 2 diabetes mellitus: a 42-month, open-label, observational, primary care study* (2006) (55)
Identification of the UBP1 Locus as a Critical Blood Pressure Determinant Using a Combination of Mouse and Human Genetics (2009) (55)
Pioglitazone and sulfonylureas: effectively treating type 2 diabetes (2007) (54)
Insulin and atherosclerosis: how are they related? (2013) (54)
The Effect of Glucose Variability on the Risk of Microvascular Complications in Type 1 Diabetes (2007) (53)
Effects of fluvastatin therapy on lipids, antioxidants, oxidation of low density lipoproteins and trace metals (1997) (52)
The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial. (2020) (52)
Basal insulin glargine and microvascular outcomes in dysglycaemic individuals: results of the Outcome Reduction with an Initial Glargine Intervention (ORIGIN) trial (2014) (48)
Leukocyte count and fibrinogen are associated with carotid and femoral intima-media thickness in a risk population for diabetes. (2002) (48)
Anomalies of lipoprotein pattern and fibrinolysis in acromegalic patients: relation to growth hormone levels and insulin-like growth factor I. (2009) (47)
Relationship between diurnal blood pressure variation and diurnal blood glucose levels in type 2 diabetic patients. (2007) (46)
Double-blind, randomized, multicentre, and active comparator controlled investigation of the effect of Pioglitazone, Metformin, and the combination of both on cardiovascular risk in patients with type 2 diabetes receiving stable basal insulin therapy: the PIOCOMB study (2011) (45)
Effect of Insulin Glargine and n-3FA on Carotid Intima-Media Thickness in People With Dysglycemia at High Risk for Cardiovascular Events (2013) (45)
Remission of type 2 diabetes following long‐term treatment with injectable testosterone undecanoate in patients with hypogonadism and type 2 diabetes: 11‐year data from a real‐world registry study (2020) (45)
Increased clearance of low density lipoprotein precursors in patients with heterozygous familial defective apolipoprotein B-100: a stable isotope approach. (1996) (44)
Effect of targeting normal fasting glucose levels with basal insulin glargine on glycaemic variability and risk of hypoglycaemia: a randomized, controlled study in patients with early Type 2 diabetes (2010) (44)
Rapid determination of total homocysteine in human plasma by using N(O,S)-ethoxycarbonyl ethyl ester derivatives and gas chromatography-mass spectrometry. (1997) (43)
Predictors of coronary heart disease and death in NIDDM: The Diabetes Intervention Study experience (1997) (41)
Impact of concentrations of glycated hemoglobin, alpha-tocopherol, copper, and manganese on oxidation of low-density lipoproteins in patients with type I diabetes, type II diabetes and control subjects. (1996) (41)
Effects of insulin glargine versus metformin on glycemic variability, microvascular and beta-cell function in early type 2 diabetes (2013) (40)
The Role of Alpha-Glucosidase Inhibitors (Acarbose) (2007) (40)
Investigation of the vascular and pleiotropic effects of atorvastatin and pioglitazone in a population at high cardiovascular risk (2008) (40)
Glibenclamide, but Not Acarbose, Increases Leptin Concentrations Parallel to Changes in Insulin in Subjects With NIDDM (1997) (40)
The role of co-morbidity in the selection of antidiabetic pharmacotherapy in type-2 diabetes (2013) (39)
A one-year study comparing the efficacy and safety of rosiglitazone and glibenclamide in the treatment of type 2 diabetes. (2007) (38)
Effect of Acarbose on Vascular Disease in Patients with Abnormal Glucose Tolerance (2008) (37)
Effect of the addition of rosiglitazone to metformin or sulfonylureas versus metformin/sulfonylurea combination therapy on ambulatory blood pressure in people with type 2 diabetes: A randomized controlled trial (the RECORD study) (2008) (37)
The Current and Potential Therapeutic Use of Metformin—The Good Old Drug (2021) (37)
Effect of the Angiotensin II Receptor Antagonist Valsartan on Lipid Profile and Glucose Metabolism in Patients with Hypertension (2001) (35)
The Metabolic Syndrome and Cancer (2013) (35)
Visfatin: a putative biomarker for metabolic syndrome is not influenced by pioglitazone or simvastatin treatment in nondiabetic patients at cardiovascular risk -- results from the PIOSTAT study. (2007) (35)
Comparative efficacy and safety of aliskiren and irbesartan in patients with hypertension and metabolic syndrome (2011) (34)
Improved glycaemic control with miglitol in inadequately-controlled type 2 diabetics. (2001) (34)
Safety profile of pioglitazone. (2001) (33)
Dapagliflozin, an SGLT2 inhibitor, for diabetes (2010) (32)
Determinants of mortality in patients with type 2 diabetes: a review (2016) (32)
The metabolic vascular syndrome - guide to an individualized treatment (2016) (32)
Urinary tract infection in patients with diabetes mellitus. (2012) (32)
Clinical efficacy and safety of cerivastatin: summary of pivotal phase IIb/III studies. (1998) (32)
The "glucose pentagon": assessing glycemic control of patients with diabetes mellitus by a model integrating different parameters from glucose profiles. (2009) (32)
Early Treatment with Basal Insulin Glargine in People with Type 2 Diabetes: Lessons from ORIGIN and Other Cardiovascular Trials (2016) (31)
Insulin Use Early in the Course of Type 2 Diabetes Mellitus: The ORIGIN Trial (2013) (31)
The role of pioglitazone in modifying the atherogenic lipoprotein profile (2009) (30)
Efficacy of α‐glucosidase inhibitors on lipids in NIDDM subjects with moderate hyperlipidaemia (1994) (30)
Differences in Glycemic Variability Between Normoglycemic and Prediabetic Subjects (2014) (29)
Influence of treatment with acarbose or glibenclamide on insulin sensitivity in type 2 diabetic patients (2003) (29)
Use of insulin in type 2 diabetes: what we learned from recent clinical trials on the benefits of early insulin initiation. (2014) (29)
Orally-Administered Chemokine Receptor CCR2 Antagonist CCX140-B in Type 2 Diabetes: A Pilot Double-Blind, Randomized Clinical Trial (2012) (27)
Long-term effect of octreotide in acromegaly on insulin resistance. (1995) (27)
Sudomotor Testing of Diabetes Polyneuropathy (2018) (27)
Effects of the dual peroxisome proliferator-activated receptor-α/γ agonist aleglitazar on renal function in patients with stage 3 chronic kidney disease and type 2 diabetes: a Phase IIb, randomized study (2014) (26)
Metabolic syndrome and its single traits as risk factors for diabetes in people with impaired glucose tolerance: the STOP-NIDDM trial (2009) (25)
Different effects of acarbose and glibenclamide on proinsulin and insulin profiles in people with Type 2 diabetes. (2002) (25)
Combining pioglitazone with a sulphonylurea or metformin in the management of type 2 diabetes (2000) (24)
Prevalence and atherosclerosis risk in different types of non-diabetic hyperglycemia. Is mild hyperglycemia an underestimated evil? (2000) (24)
Postprandial hyperglycaemia: noxious effects on the vessel wall. (2002) (23)
[Prevalence of newly diagnosed type 2 diabetes, impaired glucose tolerance and abnormal fasting glucose in a high risk population. Data from the RIAD study using new diagnostic criteria for diabetes]. (2008) (23)
["Diabetes in Germany"(DIG) study. A prospective 4-year-follow-up study on the quality of treatment for type 2 diabetes in daily practice]. (2009) (22)
Relationship between HbA1c on target, risk of silent hypoglycemia and glycemic variability in patients with type 2 diabetes mellitus. (2011) (22)
Incidence and Prevalence of Unrecognized Myocardial Infarction in People With Diabetes (2011) (21)
Rationale for Timely Insulin Therapy in Type 2 Diabetes Within the Framework of Individualised Treatment: 2020 Update (2020) (21)
A review of glucagon‐like peptide‐1 receptor agonists and their effects on lowering postprandial plasma glucose and cardiovascular outcomes in the treatment of type 2 diabetes mellitus (2017) (21)
Conversion of IGT to type 2 diabetes mellitus is associated with incident cases of hypertension: a post-hoc analysis of the STOP-NIDDM trial (2012) (20)
Relation of free and specifically bound leptin to insulin secretion in patients with impaired glucose tolerance (IGT). (2009) (20)
Impact of hormone replacement therapy on postprandial lipoproteins and lipoprotein(a) in normolipidemic postmenopausal women (1994) (20)
Work absenteeism in type 2 diabetes mellitus: results of the prospective Diabetes Intervention Study. (1993) (20)
Intima-Media-Dicke bei Gesunden ohne Risikofaktorenfür Arteriosklerose (2001) (20)
Characteristics associated with maintenance of mean A1C<6.5% in people with dysglycemia in the ORIGIN trial (2013) (20)
Beneficial effects on serum lipids in noninsulin dependent diabetics by acarbose treatment. (1991) (19)
Efficacy and Safety of 300 μg and 400 μg Cerivastatin Once Daily in Patients with Primary Hypercholesterolemia: A Multicentre, Randomized, Double-Blind, Placebo-Controlled Study (1999) (19)
Self-Monitoring of Blood Glucose (2014) (18)
Diminished susceptibility to in vitro oxidation of low-density lipoproteins in hypercholesterolemia: key role of alpha-tocopherol content. (1999) (18)
Effect of acarbose on postmeal mononuclear blood cell response in patients with early type 2 diabetes: the AI(I)DA study. (2009) (18)
Effects of the alpha glucosidase inhibitor acarbose on endothelial function after a mixed meal in newly diagnosed type 2 diabetes. (2009) (17)
Metabolic Vascular Syndrome: New Insights into a Multidimensional Network of Risk Factors and Diseases (2016) (17)
Effects of pioglitazone and/or simvastatin on low density lipoprotein subfractions in non-diabetic patients with high cardiovascular risk: A sub-analysis from the PIOSTAT study. (2008) (17)
Should antidiabetic treatment of type 2 diabetes in patients with heart failure differ from that in patients without? (2012) (17)
Relationship between adipocyte hypertrophy and metabolic disturbances. (1979) (16)
Predictors of response to early basal insulin treatment in patients with type 2 diabetes--the EARLY experience. (2014) (16)
Impaired glucose tolerance is not associated with lipid intolerance. (2002) (16)
Meta-analysis of long-term studies to assess the effect of acarbose on cardiovascular risk reduction – scientifically credible: Reply (2004) (16)
[An unusual picture of insulinoma in type-2 diabetes mellitus and morbid obesity]. (1999) (16)
Efficacy and safety of lixisenatide in patients with type 2 diabetes and renal impairment (2017) (15)
Efficacy of alpha-glucosidase inhibitors on lipids in NIDDM subjects with moderate hyperlipidaemia. (1994) (15)
The Diabetes Intervention Study (DIS): a cooperative multi-intervention trial with newly manifested type II diabetics: preliminary results. (1985) (15)
Serum and Plasma Levels of Vascular Endothelial Growth Factors in Relation to Quality of Glucose Control, Biomarkers of Inflammation, and Diabetic Nephropathy (2016) (15)
Lixisenatide Treatment for Older Patients with Type 2 Diabetes Mellitus Uncontrolled on Oral Antidiabetics: Meta-Analysis of Five Randomized Controlled Trials (2014) (15)
Mutations of the human hepatic lipase gene in patients with combined hypertriglyceridemia/hyperalphalipoproteinemia and in patients with familial combined hyperlipidemia (1999) (15)
Association of physical activity with insulin resistance, subclinical inflammation, coagulation, and fibrinolytic biomarkers among population at high risk for type 2 diabetes (2012) (15)
Very low calorie diet therapy in obese non-insulin dependent diabetes patients. (1989) (15)
Changes in insulin resistance and cardiovascular risk induced by PPARgamma activation have no impact on RBP4 plasma concentrations in nondiabetic patients. (2009) (14)
[Intima-media thickness in healthy probands without risk factors for arteriosclerosis]. (2001) (14)
[Hypoglycemia and cardiac arrhythmia in patients with diabetes mellitus type 2]. (2014) (14)
Effect of Insulin Glargine and n-3 FA on Carotid Intima-Media Thickness in PeopleWithDysglycemiaatHighRiskfor Cardiovascular Events The Glucose Reduction and Atherosclerosis Continuing Evaluation Study ( ORIGIN-GRACE ) (2013) (13)
CLINICAL RATIONALE FOR ROSUVASTATIN, A POTENT NEW HMG‐COA REDUCTASE INHIBITOR (2001) (13)
Erectile function in men with type 2 diabetes treated with dulaglutide: an exploratory analysis of the REWIND placebo-controlled randomised trial. (2021) (13)
[The metabolic syndrome and its epidemiologic dimensions in historical perspective]. (2002) (13)
The adipocyte volume in human adipose tissue: II. Observations in diabetes mellitus, primary hyperlipoproteinemia and weight reduction. (1978) (13)
Search for mitochondrial DNA mutation at position 3243 in German patients with a positive family history of maternal diabetes mellitus. (2001) (13)
Efficacy and safety of coadministration of fenofibrate and ezetimibe compared with each as monotherapy in patients with type IIb dyslipidemia and features of the metabolic syndrome: a prospective, randomized, double-blind, three-parallel arm, multicenter, comparative study. (2009) (13)
„Diabetes in Germany” (DIG)-Studie (2009) (13)
Human adipocyte volumes: Maximum size, and correlation to weight index in maturity onset-diabetes (1972) (13)
Determinants for coronary heart disease in non-insulin-dependent diabetes mellitus: lessons from the diabetes intervention study. (1996) (12)
Efficacy and Safety of Coadministration of Fenofibrate and Ezetimibe Compared with Each as Monotherapy in Patients with Type IIb Dyslipidemia and Features of the Metabolic Syndrome (2009) (12)
Serum and Plasma Levels of Vascular Endothelial Growth Factors in Relation to Quality of Glucose Control, Biomarkers of Inflammation, and Diabetic Nephropathy (2016) (12)
The metabolic syndrome--a postprandial disease? (2006) (12)
Alpha-glucosidase inhibitors for patients with type 2 diabetes: response to van de Laar et al. (2005) (12)
[History and definition(s) of metabolic syndrome]. (2007) (12)
The use of lipid-lowering therapy and effects of antihyperglycaemic therapy on lipids in subjects with type 2 diabetes with or without cardiovascular disease: a pooled analysis of data from eleven randomized trials with insulin glargine 100 U/mL (2017) (11)
Review of approved pioglitazone combinations for type 2 diabetes (2011) (11)
The anorexigenic peptide neurotensin relates to insulin sensitivity in obese patients after BPD or RYGB metabolic surgery (2018) (11)
35th Annual meeting of the European Association for the Study of Diabetes. Brussels, Belgium, 28 September-2 October, 1999. Abstracts. (1999) (11)
Effects of high doses of oestrogens and androgens on lipoproteins: observations in the treatment of excessive growth with sexual hormones. (2009) (11)
Reduced incidence of cardiovascular complications and mortality in hyperlipoproteinemia (HLP) with effective lipid correction. The Dresden HLP study. (1984) (11)
Ackerbohnenproteindiät bei Hypercholesterolämie (1983) (11)
Treatment of impaired glucose tolerance with acarbose and its effect on intima-media thickness: a substudy of the STOP-NIDDM trial (study to prevent non-insulin-dependent diabetes mellitus). (2006) (11)
Intra-individual variability and circadian rhythm of vascular endothelial growth factors in subjects with normal glucose tolerance and type 2 diabetes (2017) (11)
Stable isotope ratio analysis of amino acids: the use of N(O,S)-ethoxycarbonyl trifluoroethyl ester derivatives and gas chromatography/mass spectrometry. (1997) (11)
Polymorphisms in perilipin gene (PLIN) are not associated with obesity and weight variation in people with high risk of type 2 diabetes. (2008) (10)
Lixisenatide is Effective and Well Tolerated in Patients with Type 2 Diabetes Mellitus and Renal Impairment (2014) (10)
Impaired glucose tolerance (IGT) is not associated with disturbed homocysteine metabolism (2000) (10)
Prevalence of diabetes-specific autoantibodies in patients at risk for adult onset diabetes mellitus. (2009) (10)
Recovery of Cholesterol and Triacylglycerol in Very-Fast Ultracentrifugation of Human Lipoproteins in a Large Range of Concentrations (1994) (10)
Hypoglykämie und Herzrhythmusstörungen bei Patienten mit Diabetes Typ 2 (2014) (10)
Post-prandial hyperglycaemia and vascular disease. (2000) (10)
Elevated fasting glucose levels predicts IGT and diabetes also in middle-age subjects. (2007) (9)
Use of diethylaminoethyl-dextran (DEAE-D) in the treatment of hyperlipoproteinemias and obesity. (1987) (9)
The adipocyte volume in human adipose tissue: 1. Lipid space, normal and maximum values, and the relation to body weight index. (1978) (9)
Effects of VLCD in obese NIDDM (non-insulin dependent diabetes) on glucose, insulin and C-peptide dynamics. (1989) (9)
Glucagon as a determinant of fibrinolytic activity in men with different stages of glucose tolerance: impact of glucagon on fibrinolysis (2007) (9)
Das metabolische Syndrom: „common soil“ für Diabetes und Atherosklerose (2006) (8)
Basal and stimulated hyperinsulinemia in obesity: relationship to adipose-cell size. (1979) (8)
Relationship between diurnal glucose levels and HbA1c in type 2 diabetes. (2006) (8)
Hypoglycemia and Cardiovascular Disease: Lessons from Outcome Studies (2015) (8)
Pulse pressure is a strong predictor of cardiovascular risk: Data of the risk factors in impaired glucose tolerance for atherosclerosis and diabetes and the Sofia Metabolic Syndrome studies. (2009) (7)
Differences in the results and interpretation of oxidized LDL cholesterol by two ELISA assays--an evaluation with samples from the PIOstat study. (2009) (7)
Application of interactive multivariate data visualisation to the analysis of patient findings in metabolic research (1999) (7)
STOP-NIDDM: a new paradigm for diabetes prevention? (2002) (7)
Very Low Density Lipoprotein Overproduction Is Maximally Expressed in Early Insulin Resistant States (1999) (7)
[Diagnosis of the metabolic syndrome]. (1996) (7)
Drug therapy for the prevention of type 2 diabetes – is there a medical rationale? (2011) (7)
[Diabetes and heart failure: a practically oriented critical appraisal]. (2012) (7)
Small Dense Low‐Density Lipoprotein (LDL) in Non‐Insulin‐dependent Diabetes Mellitus (NIDDM) Impact of Hypertriglyceridemia (1997) (6)
Untersuchungen zum Verhalten von Lipiden, weiteren Serumparametern sowie Kreislauffunktionen unter UV-Einwirkung (1994) (6)
Intravenous Ferric Carboxymaltose in Patients with Type 2 Diabetes Mellitus and Iron Deficiency: CLEVER Trial Study Design and Protocol (2017) (6)
Rivaroxaban compared with low-dose aspirin in individuals with type 2 diabetes and high cardiovascular risk: a randomised trial to assess effects on endothelial function, platelet activation and vascular biomarkers (2021) (6)
Geschichte und Definition(en) des metabolischen Syndroms (2006) (6)
Grunddaten der „Diabetes in Deutschland“-Studie (DIG) (2006) (6)
Effects of a bezafibrate sustained release formulation on plasma lipoproteins in patients with hypercholesterolemia. Importance of timing of tablet intake for efficacy. (1988) (6)
Fluctuations in glycaemia in clinical diabetes mellitus type 2 are not associated with carotid intima-media thickening (2004) (6)
Is rosiglitazone associated with increased risk for cardiovascular events? (2007) (6)
Treatment: Alpha Glucosidase Inhibitors (2019) (6)
Light-to-moderate alcohol consumption, risk factor profile and early atherosclerosis: the RIAD study. (2001) (6)
Elimination of lipofundin S during the intravenous fat tolerance test in patients with low, medium, and high fasting triglyceride concentrations. (1985) (6)
Rosiglitazone Improves Postprandial Glycemia and Markers of Endothelial Function in Patients with Type 2 Diabetes (2002) (6)
Pathogenetic role of adipose tissue lipase deficit for development of hypertriglyceridaemia. (2009) (5)
Evaluation of the Potential Clinical and Economic Effects of Bodyweight Stabilisation with Acarbose in Patients with Type 2 Diabetes Mellitus (1998) (5)
[Physical training in obesity]. (1981) (5)
[Metabolic syndrome: "common soil" for diabetes and atherosclerosis. Novel approaches to an integrated therapy]. (2006) (5)
Anti-Inﬂammatory Effects of Pioglitazone and/or Simvastatin in High Cardiovascular Risk Patients With Elevated High Sensitivity C-Reactive Protein The PIOSTAT (2007) (5)
Hypertriglyceridaemia in mild hypertension: impact on cardiovascular and hormonal reactivity under different stress tests (1999) (5)
The challenge of the Metabolic Syndrome. (2007) (5)
Intima‐Media Thickness and Atherosclerotic Plaques in Familial Defective Apolipoprotein B‐100 and Familial Hypercholesterolemia (2002) (5)
Predictive value of the index of desirable body weight for total body fat mass as measured by dilution of tritiated water--problems and limitations. (1987) (5)
Erratum to: Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis (2010) (5)
The Metabolic Syndrome and Cardiovascular Diseases: An Update of Medical Treatment (2014) (5)
A new HPLC-based assay for the measurement of fructosamine-3-kinase (FN3K) and FN3K-related protein activity in human erythrocytes (2014) (5)
Outcome studies in type 2 diabetes (2005) (5)
Effect of Pioglitazone and Ramipril on Biomarkers of Low-Grade Inflammation and Vascular Function in Nondiabetic Patients with Increased Cardiovascular Risk and an Activated Inflammation: Results from the PIOace Study (2011) (5)
Primäre Prävention des Typ-2-Diabetes (2002) (5)
Metabolic Basis of Low High Density Lipoprotein in Subjects with Impaired Glucose Tolerance (1999) (5)
The Metabolic Syndrome and Cardiovascular Diseases: An Update of MedicalTreatment (2014) (5)
Effects of Pioglitazone versus Simvastatin on Biomarkers of Inflammation in Patients on High Cardiovascular Risk (2011) (4)
[Glycemic control and cardiovascular benefit: What do we know today?]. (2010) (4)
Oral glucose tolerance test: to be or not to be performed? (2002) (4)
Prädiktoren von Glukosetoleranzstörungen in einer Risikopopulation für Typ-2-Diabetes: die RIAD-Studie (2002) (4)
Clinical Impact of Titratable Fixed-Ratio Combination of Insulin Glargine/Lixisenatide vs. Each Component Alone in Type 2 Diabetes Inadequately Controlled on Oral Agents: LixiLan-O Trial (NCT02058147) (2016) (4)
[Field bean protein diet in hypercholesteremia]. (1983) (4)
Is the newly suggested fasting plasma glucose cut-off point for the diagnosis of diabetes the right one? (1999) (4)
Herausforderung Diabetestherapie : Effekte der Glitazone jenseits der Blutzuckerkontrolle (2009) (4)
Hyperinsulinemia in patients with low fractional catabolic rate of triglycerides (1981) (4)
Efficacy of a combined bezafibrate retard-colestyramine treatment in patients with hypercholesterolemia. (1990) (4)
Metabolisches Syndrom - : Quo vadis et cui bono? (2006) (4)
The future of the metabolic syndrome. (2009) (4)
[Coronary heart disease and insulin concentration in type II diabetic patients--results of a diabetes intervention study]. (1992) (3)
[Drug treatment of hyperlipoproteinemias]. (1977) (3)
[Postmenopausal hormone substitution and its effects on the climacteric syndrome, body weight and blood pressure]. (1997) (3)
More exercise for the hyperlipidaemic patients? (1988) (3)
[Different effects of fibrates on the lipoprotein profile. Comparison of the effectiveness of gemfibrozil and bezafibrate in various types of hyperlipoproteinemia]. (1992) (3)
A Practical Guide to the Therapy of Type-II-Diabetes: Pathophysiology, Metabolic Syndrome, Differential Therapy, Late Complications (1995) (3)
Erratum. Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial. Diabetes Care 2016;39:2026–2035 (2017) (3)
Definition(en) des metabolischen Syndroms (2008) (3)
[Hyperglycemia and cardiovascular events]. (2004) (3)
Influence of diet composition on insulin output, carbohydrate tolerance and lipid values in primary hypertriglyceridemia (HT). (1978) (3)
Initiation of LDL oxidation by copper ions or AAPH yields different kinetic parameters which are correlated. (1997) (3)
Insulin resistance and metabolic parameters in type 2 diabetic patients. (2002) (3)
Normnahe postprandiale Hyperglykämie - eine essenzielle Komponente guter Diabeteskontrolle und Prävention kardiovaskulärer Erkrankungen (2007) (3)
Dipeptidyl peptidase IV (DP IV)-modulations as treatment of impaired glucose tolerance and niddm (2000) (3)
Prandial hyperglycemia: is it important to track and treat? (2005) (3)
Acarbose revisited for efficacy, safety and cardiovascular benefits: a key role for controlling glycemic variability (2012) (3)
Remission of type 2 diabetes and pleiotropic effects of long-term testosterone treatment for “late-onset” hypogonadism: A case report (2019) (3)
[Relation of blood pressure to the body weight index and to metabolic parameters]. (1973) (3)
Frühe oder kurzzeitige Insulintherapie bei Typ-2-Diabetes: Stellenwert und Risiko-Nutzen-Bilanz im Rahmen individualisierter Therapiekonzepte (2019) (3)
[Predictors of abnormal glucose tolerance in persons at risk of type 2 diabetes: the RIAD study]. (2002) (3)
[Challenge in diabetes therapy: effects of glitazones beyond blood glucose control]. (2009) (3)
Individualized, patient-centered use of lixisenatide for the treatment of type 2 diabetes mellitus (2017) (3)
Th-P16:397 Atorvastatin and LDL profile in NIDDM (ALPIN study) (2006) (2)
On the determination of the distribution functions of the lipoproteins in human sera. (1972) (2)
Clinical features and treatment of coronary heart disease in diabetes (2015) (2)
[Behavior of lipids, other serum parameters and cardiovascular functions in ultraviolet therapy]. (1994) (2)
Hyperlipidämie und Fibrate unter besonderer Berücksichtigung des Diabetes (2001) (2)
Treatments for the Metabolic Syndrome (2011) (2)
Zum Beitrag: S2k-Leitlinie Diagnostik, Therapie und Verlaufskontrolle des Diabetes mellitus im Alter (2019) (2)
Acarbose monotherapy in non-insulin-dependent diabetes mellitus — the German experience (1992) (2)
Single dose treatment of type 2 diabetics by the DP IV-inhibitor P32/98 (2000) (2)
Advances in lipoprotein and atherosclerosis research : diagnostics and treatment ; proceedings of the 7th International Dresden Lipid Symposium 1991, held at Dresden, June 9-11, 1991 (1991) (2)
Frauenärztliche Aspekte des metabolischen Syndroms (2006) (2)
Aktivierungsanalytische Bestimmung von Mangan, Kupfer und Zink in Leberproben des Menschen (1975) (2)
EFFECTS OF ALEGLITAZAR ON CARDIOVASCULAR RISK FACTORS IN PATIENTS WITH STAGE 3 CHRONIC KIDNEY DISEASE AND TYPE II DIABETES (2013) (2)
Fat-cell volume in maturity-onset diabetes. (1971) (2)
Effect of Oral Antidiabetics and Insulin on Lipids and Coronary Heart Disease in Non‐Insulin‐dependent Diabetes Mellitus (1997) (2)
Comment on Ferrannini et al. CV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis. Diabetes Care 2016;39:1108–1114 (2016) (2)
Loss of fat, water, and protein during very low calorie diets and complete starvation (1987) (2)
Blutzucker-Senkung und kardiovaskulärer Vorteil: Was wissen wir heute? –Erwiderung (2011) (2)
Environmental factors and serum lipoproteins (1990) (2)
The effect of UV irradiation on lipid levels and other serum parameters and on the circulation (1994) (2)
Timing of intake of lipid lowering drugs: Is that of importance? (1989) (2)
Effect of nateglinide and glimepiride in reducing postprandial hyperglycaemia in patients with type 2 diabetes mellitus (2005) (2)
Postprandial state abnormalities: neglected cardiovascular risk factors in diabetes. Introduction. (2000) (2)
[Metabolic kinetic studies on the pathogenesis of fatty liver]. (1969) (2)
Postprandial hyperglycemia is a risk factor for cardiovascular death in newly diagnosed type 2 diabetes: The Diabetes Intervention Study (DIS) (2000) (2)
Restoring early‐phase insulin secretion – the new goal in type 2 diabetes management (2001) (2)
Fatty acid composition and action of serum lipoproteins on the PGI2-formation after various oil diets in hyperlipoproteinemia. (1984) (1)
[Cross-over comparison of fava bean protein and HLP diet in patients with hypercholesterolemia (HC)]. (1987) (1)
IMPAIRED FIBRINOLYSIS AND EARLY ATHEROSCLEROSIS IN IMPAIRED GLUCOSE TOLERANCE AND NEWLY DETECTED TYPE 2 DIABETES (1999) (1)
Is the level of steroid hormones in the low density lipoprotein (LDL) particles responsible for the prostaglandin I2 inhibitory potency of LDL? (1988) (1)
Adipositas, Bluthochdruck, Dyslipidämie und Dysglykämie - Multimodales Management gegen das metabolische Syndrom (2005) (1)
[Therapy of hypertriglyceridemia from a pathophysiological viewpoint]. (1981) (1)
Dyslipidaemia and the metabolic syndrome: critical issues in improving CVD risk reduction: (2005) (1)
[Effect of weight reduction on carbohydrate and fatty-acid metabolism in obese, maturity-onset diabetic patients]. (1975) (1)
[The metabolic syndrome: where are we going and for what benefits?]. (2006) (1)
[Significance of fatty tissue hypertrophy for the metabolic risk]. (1977) (1)
[Statistical studies on the pathogenesis of the fatty liver in diabetics]. (1967) (1)
RELATIONSHIP OF FREE FATTY ACID CONCENTRATION TO THE TURNOVER RATE OF ENDOGENOUS AND EXOGENOUS TRIGLYCERIDES (1981) (1)
[Importance of adipose tissue hypertrophy for the pathogenesis of maturity-onset diabetes]. (1975) (1)
The Metabolic Syndrome and Cardiovascular Disease (2013) (1)
[Studies on the influence of body weight and form of therapy on the development of fatty liver in maturity-onset diabetes]. (1975) (1)
Commercially sponsored supplements (1998) (1)
The Prospective Studies of Atherosclerosis (Proof-ATHERO) Consortium: Design and Rationale (2020) (1)
Physical Activity is Strongly Inversely Related To Post-Challenge Plasma Glucose and Glycemic Spikes in a Risk Population for Type 2 Diabetes (2013) (1)
Relation of lipoprotein lipase activity in adipose tissue to adipocyte volume and its influence in hypertriglyceridemia pathogenesis. (1977) (1)
[Intensive basic therapy decreases the need for drug treatment and improves glucose control: an important result of the diabetes intervention study]. (1988) (1)
Shifting the Disease Management Paradigm From Glucose (2009) (1)
Therapeutical Effects of Endurance Training in Primary Hyperlipoproteinemia (1983) (1)
[Screening, prevention and early therapy of type 2 diabetics]. (2004) (1)
Hypertriglyceridemia--independent risk factor or risk marker? (1989) (1)
[Cardiologic findings in newly manifested type II diabetics of the diabetes intervention study]. (1986) (1)
Impaired glucose tolerance, the metabolic syndrome and carotid intima-media thickness: The riad study (1999) (1)
[Early detection of diabetes in visitors to a health fair according to new definition of diabetes]. (1998) (1)
[Guidelines for the treatment of hypercholesterolemia]. (1990) (1)
2.P.199 Significance of insulin like growth factor 1 for macro- and microangiopathy in non-insulin-dependent diabetes mellitus (1997) (1)
[Modern medical treatment of type 2 diabetes]. (2014) (1)
[Coronary heart diseases and associated risk factors in newly manifested type II diabetic patients over the course of 5 years]. (1989) (1)
Metabolic effects of weight reduction in obese diabetics and nondiabetics. (1976) (1)
Coronary Risk Factors in Adults: The Influence of Nutrition in Early Life (1977) (1)
[Hyperlipidemia and fibrates with special reference to diabetes]. (2001) (1)
[On the problems of the significance of paraproteinemia]. (1967) (1)
Decreasing Postprandial Plasma Glucose Using an α-Glucosidase Inhibitor in Subjects with IGT for the Prevention of Type 2 Diabetes Mellitus: The STOP-NIDDM Trial (2012) (1)
[Postprandial hyperglycemia as a risk factor for cardiovascular disease. Therapy improves prognosis]. (2004) (1)
New aspects of turnover of endogenous and exogenous triglycerides. (1987) (1)
Cross-over Vergleich von Ackerbohnenprotein- und HLP-Diät bei Patienten mit Hypercholesterolämie (HC) (1987) (1)
Metabolisches Syndrom und Insulinresistenz (2017) (1)
PIOcomb-Studie: Die Kombination von Pioglitazon mit Insulin glargine führt zu einer Verbesserung von Biomarkern der Insulinresistenz, β-Zellfunktion und der chronisch systemischen Inflammation (BEVAIR-Konzept) (2011) (1)
Knochenschmerzen im letzten Drittel der Schwangerschaft (1999) (1)
Frühe Insulintherapie im Netzwerk individualisierter Therapie des Typ-2-Diabetes (2012) (1)
HYPERTRIGLYZERIDAMIEN ALS EIGENSTANDIGER RISIKOFAKTOR : KONSEQUENZEN FUR DIE THERAPIE (1992) (1)
Die Diabetesinterventionsstudie DIS - eine multizentrische Interventionsstudie bei Typ-II-Diabetikern (1994) (1)
Praxis der Insulintherapie bei Typ 2 Diabetikern im Rahmen der DIG-(Diabetes in Germany) Studie (2006) (1)
Primär- und Sekundärprävention bei Männern und Frauen mit Typ 2 Diabetes in Deutschland: Die Diabetes in Germany (DIG)-Studie – eine prospektive 4-Jahres-Studie zur Therapiequalität des Metabolischen Syndroms sowie der Hypercholesterolämie (2009) (1)
Postprandiale Hyperglykämie als Risikofaktor bei Herz-Kreislauf-Erkrankungen (2004) (1)
Abstract 4433: Comparative Effects of Aliskiren and Irbesartan on Blood Pressure, Renin System Activity, and Biomarkers of Cardiometabolic Risk in Patients with Hypertension and Metabolic Syndrome (2008) (0)
[Changes in fat and carbohydrate metabolism after administration of cholinomimetic agents in anesthetized rats]. (1970) (0)
Correction to: Intravenous Ferric Carboxymaltose in Patients with Type 2 Diabetes Mellitus and Iron Deficiency: CLEVER Trial Study Design and Protocol (2018) (0)
[Controlled studies in German language publications]. (2008) (0)
THERAPY OF HYPERTRIGLYCERIDEMIA (HTG) FROM THE PATHOPHYSIOLOGIC POINT OF VIEW (1981) (0)
Editor's introduction (2000) (0)
Case Control Study of Systemic Biomarkers Related to Diabetic Macular Edema in Patients with Type 2 Diabetes (2015) (0)
[Modern treatment of diabetes mellitus with sulfonylurea compounds]. (1979) (0)
RATIONALE THERAPIE DES TYP-II-DIABETES (1996) (0)
[Biopsy and metabolic findings in blood donors having elevated aminotransferases]. (1969) (0)
[Role of very-low-density lipoproteins in the pathogenesis of primary hypertriglyceridemia]. (1970) (0)
[Therapy decision based on the glucose triad. Drug treatment of type 2 diabetes]. (2003) (0)
[Statistical studies on the effect of diabetes type and its treatment on the extent and occurrence of fatty degeneration of the liver in diabetes mellitus]. (1967) (0)
[Glucose-independent impact of the glitazones on the cardiovascular outcome]. (2005) (0)
2.P.236 A gas chromatography/mass spectrometry method for the quantitation of total homocysteine in human plasma (1997) (0)
Evaluation der Wirksamkeit von retardierter Nikotinsäure im Vergleich zu Placebo auf die postprandiale Hypertriglyzeridämie bei Patienten mit Metabolischem Syndrom (2010) (0)
[Liver findings in primary hyperlipoproteinemia (HLP)]. (1973) (0)
Application of interactive multivariate data visualisation to analysis of metabolic parameters in dependence on the stage of glucose tolerance and impaired fasting glucose (2000) (0)
To: Strey CH, Young J, Collier M, Florkowski CM, Shand BI, Scott RS (2004) The postprandial state does not impair endothelial function in women with Type 2 diabetes irrespective of glycaemic control. Diabetologia 47:1838–1846 (2005) (0)
Personen mit Prädiabetes haben höhere Triglyzeridwerte als Personen im Stadium der normalen Glukosetoleranz (2006) (0)
Differential therapy of Type 2 Diabetes based on underlying pathophysiology (2002) (0)
ALTERATIONS OF INSULIN SECRETION MODIFYING TRIGLYCERIDE TURNOVER (1981) (0)
[Biopsy and metabolic findings in blood donors with increased transaminases]. (1969) (0)
[Metabolic syndrome]. (1996) (0)
PIOcomb Studie: Die Kombination von Pioglitazon mit Insulin Glargine verbessert die Zusammensetzung der Cholesterin Subfraktionen bei Patienten mit Typ 2 Diabetes mellitus (2011) (0)
1.P.296 Triglycerides in familial combined hyperlipidemia (FCHL): Heredity and association with atherosclerotic findings (1997) (0)
6.3 Efficacy and Safety of Lixisenatide in Elderly T2DM Patients: Subanalysis from the GetGoal Program (916-P) (2013) (0)
Investigations on the role of low density lipoproteins in the pathogenesis of the essential carbohydrate-induced hypertriglyceridemia (1970) (0)
[Integrated drug therapy of the metabolic syndrome]. (1996) (0)
Incidence of coronary heart disease in type-II-diabetes: Impact of quality of metabolic control (1995) (0)
1.P.48 Functional implications of the human lipoprotein lipase Asp9Asn variant: Insights from in vivo kinetic studies (1997) (0)
Efficacy and Safety of Lixisenatide in Elderly Type 2 Diabetes Mellitus Patients: Subanalysis from the GetGoal Program (2013) (0)
[The new oral antidiabetics. Type 2 diabetes under control only with tablets?]. (2001) (0)
The importance of oxidative stress in different stages of coronary artery disease (CAD) (1999) (0)
Impact of obesity on coagulation/fibrinolysis system in Type II diabetics (1994) (0)
Der Einfluss von Acarbose auf die postprandiale Endothelfunktion bei Typ-2-Diabetes (2008) (0)
Determination of manganese, copper, and zinc in human liver specimens by activation analysis (1975) (0)
2.P.88 Fluvastatin in higher dosage reduces also triglyceride rich lipoproteins (1997) (0)
7.5 Oral hypoglycemics (1995) (0)
Leucocytes count and fibrinogen level are associated with carotid and femoral intima-media thickness (2000) (0)
Einfluss von Hypoglykämien auf die akute Herzfunktion bei Typ 2 Diabetes-Patienten: Simultane CGM- und EKG- Messungen unter Therapie mit DPP-4 Inhibitoren Vildagliptin und Sitagliptin bei Insulin-behandelten Patienten (2013) (0)
Das Metabolische Syndrom aus ernährungsmedizinischer Sicht (2003) (0)
[Methodical studies and directions for the measurement of fatty acid curves in capillary blood]. (1970) (0)
Fatty acid metabolism and vascular complications in diabetics (1975) (0)
Dyslipidemia in the Metabolic Syndrome (2005) (0)
Effects of the angiotensin-II-antagonist valsartan on blood lipids and glucose in hypertensive patients (2000) (0)
Evaluation der Wertigkeit von RBP4 als Marker des metabolischen Syndroms in einer prospektiven Interventionsstudie mit Pioglitazon (2007) (0)
[Studies on the relation between hepatic lipid content and reactive hepatitis]. (1972) (0)
Former-GDR perspective (1992) (0)
[Rational therapy of Type II diabetes]. (1996) (0)
Importance of Hypertriglyceridemia as an Independent Risk Factor: Investigations with Familial Combined Hyperlipidemia and Familial Hypertriglyceridemia (1987) (0)
Effects of Chenodeoxycholic Acid (CD) Treatment on Endogenous Plasma Triglyceride (TG) Transport in Hyperlipoproteinemia (HLP) (1978) (0)
1.P.49 Direct effects of the Asn291Ser variant of the human lipoprotein lipase on the catabolism of VLDL1 and VLDL2 in vivo (1997) (0)
Hypoglycemia is associated with acute changes in the QTc interval and reduced heart rate in type 2 diabetic patients with cardiovascular disease in a real world setting (2017) (0)
Hintergrund und Design der TECOS-Studie (Trial Evaluating Cardiovasular Outcomes with Sitagliptin) (2011) (0)
The metabolic syndrome - obesity and hypertension. (2003) (0)
[Studies on the effect of essential phospholipids in the essential hypertriglyceridemia]. (1969) (0)
[Presentation of an insulin-treated patient group within the scope of a 5-year study of the Diabetes Intervention Study (DIS)]. (1987) (0)
[In high risk for diabetes should drugs be used for prevention? (interview by Dr. Judith Neumaier)]. (2002) (0)
Lipidomic strategies to analyze type 2 diabetes from early insulin resistance to the metabolic syndrome (2009) (0)
Comparative investigation of basal insulin glargine versus metformin as first line drug in patients with type 2 diabetes on B-Cell and endothelial function (2012) (0)
Therapie des Diabetes mellitus (2000) (0)
[Multimodal therapy of dyslipidemia]. (2011) (0)
Evaluierung der Glukosewerte im Tag/Nacht- Profil bei mit Insulin behandelten Patienten mit Typ 2 Diabetes: Ergebnisse einer explorativen Studie mit kontinuierlichem Glukosemonitoring (CGM) (2010) (0)
[Physiopathology and clinical aspects of lipid metabolism disorders. Physiopathology of lipid metabolism from the clinical viewpoint]. (1971) (0)
Erratum (1999) (0)
PDB18 COST-EFFECTIVENESS OF ACARBOSE IN PATIENTS WITH TYPE-2 DIABETES IN THREE COUNTRIES (2006) (0)
[The diagnostic value of the D-xylose test]. (1966) (0)
Pro12Ala Polymorphism of the Peroxisome Proliferator-Activated Receptor-γ2: Association to Type 2 Diabetes and Response to a Glucose Tolerance Test in a Risk Population for Diabetes (2002) (0)
8.2 Treatment of dyslipoproteinemia (1995) (0)
Einfluss der Qualität der Diabeteskontrolle auf systematische Vascular Endothelial Growth Factors (VEGF) und Biomarker der subklinischen Inflammation bei Typ 2 Diabetes (2016) (0)
Impaired glucose tolerance is not associated with lipidintolerance (2000) (0)
[Results of protein-sparing modified fasting in hyperlipoproteinemias]. (1985) (0)
Einfluss einer PPARγ Stimulation auf den postprandialen Glukosemetabolismus und die Proinsulinsekretion der Betazelle bei kardiovaskulären Risikopatienten ohne manifesten Diabetes mellitus (2006) (0)
Very low density lipoprotein overproduction is maximally expressed in insulin-resistant states (1998) (0)
Effects of aleglitazar on cardiovascular risk factors in patients with stage 3 chronic kidney disease and type 2 diabetes (2013) (0)
Low high density lipoprotein (HDL) and impaired glucose tolerance: Insights from stable isotope studies (2000) (0)
EFFECTS OF THE ANGIOTENSIN-II-ANTAGONIST VALSARTAN ON BLOOD LIPIDS AND GLUCOSE IN HYPERTENSIVE PATIENTS: P2.6 (2000) (0)
Diabetesfrüherkennung bei Besuchern eines Gesundheitstages nach der neuen Diabetesdefinition (1998) (0)
Metabolic rates and substrate oxidation in patients with diabetes mellitus type II and hypertriglyceridemia (1994) (0)
Microalbuminuria is a strong risk factor for atherosclerosis in various degrees of glucose tolerance (2000) (0)
Regulation der intestinalen Inflammation durch Acarbose (2016) (0)
[Is primary or secondary prevention of diabetes mellitus in hyperliporoteinemia possible under long-term clofibrate therapy?]. (1976) (0)
Der Pulsdruck bei Typ-2–Diabetikern mit Herzinfarkt: die DIG Studie (2007) (0)
[Vascular complications in primary hyperlipoproteinemias (HLP) with special reference to changes in the eye fundus]. (1979) (0)
[Determination of lipoprotein lipase activity in the epididymal fatty tissue of the rat and its relation to the volume of adipocytes]. (1977) (0)
Introduction: new approaches to managing diabetic dyslipidaemia. (2005) (0)
Hypertriglyceridaemia (HTG) as independent risk factor for myocardial infarction in type 2 diabetes: The Diabetes Intervention Study (1993) (0)
Long-term results of improved dietery compliance in the diabetes intervention study (1995) (0)
Very fast ultracentrifugation (VFU) of plasma lipoproteins (1994) (0)
Postprandial hyperglycemia but not fasting blood glucose is a risk factor for cardiovascular death in type 2 diabetes: The diabetes intervention study (DIS) (2000) (0)
Susceptibility to oxidation of LDL is diminished in postmenopausal women who take estrogens (1994) (0)
The metabolic syndrome—Common soil for diabetes and cardiovascular disease (2006) (0)
Relationship between vascular endothelial growth factor (VEGFA), biomarkers of inflammation and dysglycemia (2014) (0)
[Alcohol and lipid metabolism]. (1981) (0)
[Statistical investigations into pathogenesis of fatty liver. II. Pathogenic factors of steatosis hepatitis]. (1968) (0)
Lipidomics in type 2 diabetic patients treated with an intestinal absorption inhibitor versus placebo: implications on metabolic learning and intestinal mucosa transdifferentiation (2008) (0)
Die Kombination von Pioglitazon mit Insulin ist gut verträglich und vorteilhaft im Vergleich zur Kombination von Insulin mit Metformin. Ergebnisse der PIOcomp-Studie (2010) (0)
Peroxisome proliferator activated receptor (PPAR) γ2-Pro12Ala-mutation and early atherosclerosis: the RIAD study (2001) (0)
[Volumes of isolated human fat cells--their distributory, maximum size, and relation to the weight index]. (1971) (0)
[Therapy of hyperlipoproteinemias]. (1980) (0)
[Significance of triglycerides for other metabolic parameters in the familial metabolic syndrome]. (2003) (0)
[Free fatty acids in microsamples of capillary blood: fasting levels, progress curves and daily profiles]. (1972) (0)
[Statistical studies on the pathogenesis of fatty liver. I. Fatty liver and latent diabetes mellitus]. (1968) (0)
Microalbuminuria is an independent risk factor for increased intima-media thickness: Data from the riad study (1999) (0)
Frequency and severity of insulin resistance in type 2 diabetes (2000) (0)
Protective effect of the pro12Ala variant of the human peroxisome proliferator activated receptor γ2 on obesity, insulin sensitivity and glucose tolerance (2000) (0)
Correlation between VEGF-A, biomarker of inflammation and dysglycemia (2014) (0)
Increased cholesterol ester transfer protein (CETP) activity modulates composition and metabolic clearance of HDL in insulin resistant states (1999) (0)
Relationship between glucagon in a lipid-glucose load and carotid intima-media thickness (2000) (0)
[Clinical studies on the effect of Regadrin of the VEB Berlin-Chemie in the treatment of essential hyperlipemias]. (1970) (0)
The metabolic syndrome and cardiovascular disease - an ongoing tsunami. (2013) (0)
[Determination of total body fat by tritium dilution: method and relation of the results to body-mass-index (BMI)]. (1988) (0)
[Nutrition in hyperlipoproteinemias from the preventive and therapeutic viewpoint]. (1984) (0)
Aussagekraft von Lipoproteinbestimmungen für die klinische Beurteilung des Effektes der Bewegungstherapie (1984) (0)
[Differential type 2 diabetes therapy based on pathophysiological aspects]. (2002) (0)
[Changes in metabolic parameters, especially in fat metabolism, in chronic alcoholics during clinical alcohol deficiency]. (1972) (0)
GW24-e3085 The dual PPAR alpha/gamma agonist aleglitazar has a beneficial effect on atherogenic dyslipidemia in patients with type 2 diabetes (2013) (0)
[On the diagnosis of Waldenström's macroglobulinemia]. (1966) (0)
Persons with impaired glucose tolerance have higher triglyceride values and insulin resistance than persons with normal glucose tolerance (2007) (0)
PC-FUNKTIONALITAT MIT SPS-STABILITAT (1998) (0)
Wirkungen physischer Konditionierung im Rahmen der Kurorttherapie auf den Lipidmetabolismus (1990) (0)
Abstract-Thema: Pioglitazone und Simvastatin haben komplementäre Effekte auf die subklinische Entzündung bei Patienten mit erhöhtem kardiovaskulären Risiko: Die Piostat-Studie (2006) (0)
Hepatic oversecretion of small, cholesterol-rich very low density lipoproteins (VLDL2, SF 20–60) in familial combined hyperlipidemia (FCHL) (2000) (0)
EASD News Section January 2004 (2004) (0)
[Primary prevention of type 2 diabetes]. (2002) (0)
STOFFWECHSELERKRANKUNGEN ALS POTENTIELLES PARODONTITISRISIKO (1999) (0)
Grundriß der Ernährungslehre. 2. Aufl. Herausgegeben von H.‐A. Ketz. 410 Seiten, 117 Tab., 95 Abb. VEB Gustav Fischer Verlag, Jena 1984. Preis: DDR 41,00 M; Ausland 51,00 M (1985) (0)
Signifikanz des Metabolischen Syndroms als kardiovaskulärer Risikofaktor bei Typ 2 Diabetes: Hat das Metabolische Syndrom ein höheres Risiko als die Einzelkomponenten? Ergebnisse der DIG-Studie (2007) (0)
Beziehungen zwischen latenten nächtlichen Hypoglykämien, Nüchternglukose und postprandialen Glukoseverläufen nach einem standardisierten Frühstück bei insulinpflichtigen Typ 2 Diabetikern ermittelt mittels kontinuierlichem interstitiellen Glukosemonitoring (2009) (0)
Moderne medikamentöse Therapie des Typ-2-Diabetes – Hin zur personalisierten Therapie (2015) (0)
Direkter Angriff auf das kardiovaskulsre Risiko (2005) (0)
Zum Beitrag: „Testosteronmangel im Alter – was ist zu tun“ (2021) (0)
Albuminurie und Typ 2-Diabetesrisiko – Eine prospektive Studie (2010) (0)
Multimodale Lipidtherapie bei Diabetes (2012) (0)
Hat die Blutdruckamplitude (Pulspressure) Einfluss auf die Proteinurie bei Patienten mit Diabetes mellitus Typ 2 (2006) (0)
Therapiequalität bei Typ-2-Diabetes in Deutschland: Die DIG-Studie (Diabetes in Deutschland): Basisdaten und 2-Jahres-Untersuchung (2008) (0)
[Studies on the effect of essential phospholipids in essential hypertriglyceridemia]. (1969) (0)
Metabolisches Syndrom und seine Komponenten als Risikofaktoren für Diabetes bei Personen mit gestörter Glucosetoleranz: Ergebnisse der STOP-NIDDM Studie (2008) (0)
Vergleich der Sterblichkeitsraten bei Typ 2 Diabetikern in Deutschland im Rahmen der DIG-Studie zu den Ergebnissen der Studien ACCORD, ADVANCE und VATD (2009) (0)
KONSEQUENZEN UND PRAXIS DER THERAPIE : FETTSTOFFWECHSELSTORUNGEN IM ALTER (1996) (0)
Diagnostischer Wert von klinischen Befunden und Biomarkern als mögliche Risikofaktoren für die diabetische Retinopathie: Ergebnisse einer Kohortenstudie mit optischer Kohärenztomografie (OCT) (2019) (0)
»Dresdner Trunk« - proteinsubstituiertes modifiziertes Fasten (2004) (0)
Normnahe Blutzuckerkontrolle oder HbA1c < 7 % bei Typ-2-Diabetes – hat 2008 die diabetologische Weltsicht erschüttert oder dringt die Sonne durch den Nebel? (2009) (0)
[The relation between lipoprotein fractions, sex and IHD in patients with primary hyperlipoproteinemia]. (1982) (0)
intima-media thickening Fluctuations in glycaemia in clinical diabetes mellitus type 2 are not associated with carotid (2012) (0)
Vergleich der Parameter der Blutzuckerexkursion nach einer Testmahlzeit bei Typ-2-Diabetikern unter Glargin- vs. Metformin-Monotherapie bei normnahnen HbA1C-Werten (2008) (0)
Auswirkung von Pioglitazon und Simvastatin auf die Plasmaspiegel von Visfatin und Adiponektin bei Nichtdiabetikern (2006) (0)
Mittels CGMS ermittelte Determinanten für Hypoglykämien bei Typ 2 Diabetikern mit normnahen HbA1C-Werten (2009) (0)
Auswirkungen von Depot-Exenatide auf kardiovaskuläre Endpunkte bei Patienten mit Typ-2-Diabetes mellitus: Ergebnisse der EXSCEL-Studie (2018) (0)
Wirksamkeit und Sicherheit von Albiglutid bei Patienten mit Typ 2 Diabetes und gestörter Nierenfunktion: Ergebnisse der HARMONY 8 Studie (2014) (0)
[Effect of chlorfibrinic acid on the triglyceride and glycogen contents of human liver as well as on blood-level forming metabolites]. (1972) (0)
Dyslipidämie ist bereits im normotensiven Bereich mit Störungen der Blutdruckregulation assoziiert (2006) (0)
Moderne medikamentöse Therapie des Typ-2-Diabetes (2014) (0)
[Results of linseed oil and olive oil therapy in hyperlipoproteinemia patients]. (1984) (0)
Effekt der Acarbose-Behandlung im Vergleich zu Placebo auf die Leukozytenzahl vor und nach einer Testmahlzeit: The Effect of Acarbose on sub-clinical Inflammation and Immune-response in early type 2 Diabetes and risk of Atherosclerosis (AI(I)DA) Studie (2007) (0)
Effizienz und Sicherheit eines neuen Chemokin Rezeptor 2 Antagonist, CCX140-B bei Patienten mit Typ 2 Diabetes (2012) (0)
The plurimetabolic syndrome and mortality: the diabetes intervention study (1994) (0)
Comparative investigation of basal insulin glargine versus metformin treatment in drug naive type 2 diabetes patients: results of the GLORY study (2012) (0)
Koronare Herzkrankheiten (KHK) und das Risiko von KHK bei Patienten mit Typ 2 Diabetes: Die Diabetes in Germany (DIG) Studie (2007) (0)
Modifikation des Fettverzehrs bei Typ II-Diabetikern: Was kann erreicht werden? (1993) (0)
Zusammenhang von Parametern der subklinischen Inflammation zur Adipositas in einer normoglykämischen Risikopopulation für Typ 2 Diabetes: Die RIAD Studie (2003) (0)
Untersuchungen zum Einfluss von Pioglitazon und Simvastatin auf die Leberfunktion bei Hoch-Risiko-Patienten für KHK mit nachgewiesener subklinischer Inflammation (2008) (0)
Störungen des Lipid- und Lipoproteinstoffwechsels (2000) (0)
Vergleichende Untersuchungen über die capillarvenöse Blutzuckerdifferenz unter besonderer Berücksichtigung des Hungergefühls (1962) (0)
Postprandial Glucose New Implications Regulation: New Data and (2005) (0)
Messung des Bauchumfanges – eine einfache Screeningmethode für Typ 2 Diabetes? (2011) (0)
Ein einfacher Score zur Früherkennung von Diabetes mellitus Typ2 und Metabolischem Syndrom (2012) (0)
Multimodale Therapie von Fettstoffwechselstörungen (2011) (0)
Praxis der Insulintherapie bei Typ 2 Diabetikern in Deutschland: erste Ergebnisse der Diabetes in Germany (DIG) Studie (2006) (0)
Hyperlipoproteinämien bei Typ II-Diabetikern, Untersuchungen zu Prävalenz, Inzidenz und Behandlungsergebnissen (1992) (0)
[Problems of long-term treatment of hyperlipoproteinemia with clofibrinic acid]. (1973) (0)
Metabolische Ursachen einer differenten Energieverwertung bei adipösen Männern und Frauen (1992) (0)
Postprandialer Status und subklinische Entzündung bei neu entdecktem Typ 2 Diabetes – die AI(I)DA-Studie (Wirkung von Acarbose auf die subklinische Inflammation und Immunantwort bei Typ 2 Diabetes und das Arterioskleroserisiko) (2007) (0)
Zur Epidemiologie der Hypertonie bei definierten Stoffwechselstörungen (1981) (0)
Vergleich der Versorgung von geriatrischen Diabetikern in Pflegeheimen mit geriatrischen Diabetikern, die im häuslichen Wohnumfeld leben in einer ländlichen Region Sachsens (2008) (0)
Insulintherapie bei Diabetes mellitus Typ 2: patientenzentriert, rechtzeitig, nutzen-risiko-bilanziert; Standortbestimmung 2019 nach dem ADA/EASD-Konsensus 2018 (2020) (0)
Beziehung zwischen HbA1c- Zielwert der ADA und glykämischer Variabilität sowie Auftreten und Dauer latenter Hypoglykämien bei Patienten mit Diabetes mellitus Typ 2 (2009) (0)
Adiponectin und Leptin: postprandialer Verlauf und die Beziehungen zu den Parametern der Insulin-Glukose-Homöostase in verschiedenen Glukosetoleranzstadien (2003) (0)
Moderne Fettstoffwechseltherapie bei Patienten mit Diabetes mellitus – Was ist neu? (2013) (0)
Untersuchung der Glukoseschwankungen von gesunden Probanden, Prädiabetikern und Diabetikern erhoben mittels continuous glucose measurement system (CGMS) (2009) (0)
Unterzuckerung und Herzerkrankung - eine komplikationsreiche Verbindung (2015) (0)
Medikamentöse Prävention des Diabetes mellitus Typ 2 – Wenn eine Lebensstiländerung nicht ausreicht ... (2008) (0)
Beziehungen zwischen Hypoglykämien, Glukoseschwankungen und Arrhythmien bei Patienten mit Diabetes mellitus Typ 2 und kardiovaskulären Erkrankungen (2012) (0)
Diabetologie und Stoffwechsel (2017) (0)
Beziehung Zwischen Komponenten Des Metabolischen Syndroms Und CRP Im Kontext Mit Etablierten Risikofaktoren In Einer Hochrisikogruppe Für Koronare Herzkrankheit (2006) (0)
[Interpretation of oral glucose tolerance tests]. (2009) (0)
Wechselbeziehungen zwischen Energieverwertung, Na-K-ATPase-System und Fettgewebslipolyse bei Adipositas (1991) (0)
Das „Glukosepentagon“– ein Modell zur Vereinigung der langfristigen und akuten glykämischen Einstellung (2010) (0)
Vergleich der Therapiequalität des Typ 2 Diabetes im Rahmen einer Diabetesvereinbarung auf der Grundlage von Praxisleitlinien mit der Qualität der Therapie ohne eine solche Vereinbarung: Die DIG-Studie (Diabetes in Germany) (2007) (0)
Patienten mit neu entdecktem Diabetes mellitus Typ 2 haben signifikant höhere Triglyzeridwerte als Patienten mit normaler und gestörter Glukosetoleranz (2006) (0)
Effekte einer Therapie mit Pioglitazon und oder Simvastatin auf verschiedene Parameter des metabolischen Syndroms bei kardiovaskulären Risikopatienten ohne manifesten Diabetes mellitus (2006) (0)
[Activation analysis of human tissue samples: manganese, copper, and zinc in the liver]. (1973) (0)
Bedeutung der Triglyzeride für weitere metabolische Parameter bei familiärem metabolischem Syndrom (2003) (0)
Adiponektin / Leptin-Ratio als Marker der Insulinresistenz (2006) (0)
Risikofaktoren für kardiovaskuläre Komplikationen und Mortalität in einer bevölkerungsbasierten prospektiven Studie von Patienten mit Typ 2 Diabetes: Die Diabetes In Germany (DIG) Studie (2009) (0)
Risikofaktoren für Intima-Media-Verdickung: Ist Adiponektin ein unabhängiger Risikofaktor? Die RIAD Studie (2006) (0)
Screening, Prävention und frühe Therapie des Typ 2 Diabetes: Die Bestimmung des Nüchternblutzuckers reicht nicht aus (2004) (0)
Untersuchung zur retinalen Gefäßfunktion bei gut eingestellten Typ-2-Diabetikern mittels dynamischer retinaler Gefäßanalyse (2008) (0)
Beziehung zwischen Metabolischem Syndrom und Gefäßendothel – eine Beobachtung der RIAD-Studie (2006) (0)
Blutdruck und Nierenfunktion unter einer Therapie mit Insulin Glargine in Kombination mit Pioglitazon und/oder Metformin. Ergebnisse der PIOCOMB-Studie (2011) (0)
Glukagon determiniert PAI-1 und t-PA – Aktivität bei Männern mit normaler Glukosetoleranz (2006) (0)
[Significance of fatty liver as an early symptom of diabetes mellitus and hyperlipoproteinemias]. (1974) (0)
Glukotrias als Basis: So stellen Sie Ihren Typ 2 Diabetiker richtig ein (2003) (0)
Pioglitazon in Kombination mit Atorvastatin verbessert die endotheliale Funktion und reduziert das kardiovaskuläre Risikoprofil (2008) (0)
5.6 Disturbances in the liver and biliary system (1995) (0)
[Analysis of steatosis-promoting factors in patients with fatty liver of a large blood donors collective]. (1969) (0)
[Preliminary report on electronic measurement of volume distribution curves of isolated human fatty cells in obesity and their relations to diabetes mellitus]. (1970) (0)
Preprandial complementary insulin therapy in overweight patients with type 2 diabetes with regular insulin or with rapid acting insulin analogs (2000) (0)
Die ACCORD-Studie und die Probleme bei der Interpretation der Ergebnisse (2008) (0)
[The value of hypertension and metabolic factors on the development of coronary heart disease in type II diabetic patients]. (1988) (0)
[Physiopathology and clinical aspects of lipid metabolism disorders. Clinical aspects and therapy of primary hyperlipoproteinemias]. (1971) (0)
Impact of concentration of glycosylated hemoglobin on the lagtime of oxidizability of low-density lipoproteins (1995) (0)
Risk Factors in Insulin Dependent Diabetics (1983) (0)
[Effect of propranolol and chlorophenoxybutyric acid (CPJB) on the dynamics of free fatty acids and blood sugar]. (1972) (0)
Arteriosklerose und Diabetes – die Common-soil-Hypothese (2004) (0)
Hyperinsulinemia in obesity: Importance of adipose tissue cell size (1983) (0)
Findings from Preventive Type 2 Diabetes Trials (2005) (0)
1. Classification and epidemiology (1995) (0)
RELATIONSHIP BETWEEN SERUM LIPOPROTEIN FRACTIONS, SEX AND ISCHEMIC HEART DISEASES IN HYPERLIPOPROTEINEMIA (1981) (0)
Hyperlipoproteinaemia in diabetes mellitus II in the diabetes intervention study - 5 year report on prevalence, course and treatment results. (1990) (0)
Risk factors for early atherosclerosis in a population at risk for diabetes: the riad study (2001) (0)
Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients Meta-analysis of risk improvement under acarbose (2003) (0)
Prevalence and rapid diagnostic of the apolipoprotein E Arg136 - > Cys mutation (1995) (0)
Abnormal lipid tolerance in subjects with impaired glucose tolerance and type 2 diabetes: Relationship to intima-media thickness (1999) (0)
Einfluss von zwei Kostformen zur Gewichtsreduktion auf den 72-Stunden-Blutzuckerverlauf (CGMS) bei Typ-2-Diabetikern (T2DM) (2008) (0)
Metabolic transdifferentiation of the intestinal mucosa in early stage type 2 diabetes and metabolic syndrome – the influence of Acarbose (2008) (0)
The free fatty acids in microsamples of capillary blood: fasting values, course and daily profile. (1972) (0)
[Clinical studies on a new preparation for the probeless determination of gastric acidity]. (1966) (0)
[Peculiarities of infusion therapy and parenteral nutrition in hyperlipoproteinemia]. (1980) (0)
[Bone pain in the last pregnancy trimester]. (1999) (0)
Dedication to Professor Hans Haller on Occasion of His 65th Birthday (2009) (0)
Kontrollierte Studien in deutschsprachigen Publikationen (2008) (0)
[Diagnostic and physiopathologic evidence by micro-lipid determination in liver punctures]. (1970) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Markolf Hanefeld?

Markolf Hanefeld is affiliated with the following schools: